Aclarubicin (HCl)

Drug #29

Aclarubicin (HCl) is antibiotic with antineoplastic or anticancerous properties, belonging to the anthracycline group. Aclarubicin (HCl) is effective in the treatment of different cancers (leukemias) to slow or stop the growth of cancerous cells or abnormal cells. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously.

← Previous drug Next drug →

Primary Characteristics

It is of Semi Synthetic origin and belongs to Anthracycline.

It belongs to Intercalation (DNA acting) pharmacological group on the basis of mechanism of action and also classified in Antineoplastic Agent pharmacological group. It is also classified under Chemotherapeutic Regimens .

Molecular Weight: 848.3 · pK_a: 7.3 · Solubility in Water: freely soluble · Solubility in Alcohol: soluble · Non-proprietary name: Aclarubicin (HCl).

Molecular structure of Aclarubicin (HCl)

Pharmacokinetics

Distribution: Aclarubicin (HCl) has a volume of distribution is 657 ± 341 litre. plasma protein binding is 43%.

Elimination: it is metabolised via extensive, plasma half-life is 1.4-8.5 hr.

Indications

Aclarubicin (HCl) is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer.

Contraindications

Aclarubicin (HCl) is contraindicated in conditions like Neutropenia, Thrombocytopenia, Cardiac failure.

Dosage

Aclarubicin (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
62.5 mg/sq.meter	62.5 mg/sq.meter	—	IV	Maintenance, Every 3-4 Weeks
237 mg/sq.meter	237 mg/sq.meter	Every 24h	IV	Initially for 3-7 Days
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Aclarubicin (HCl) in overdosage may give rise to further complications which include Hepatic insufficiency, Reversible ECG changes, Sinus tachycardia , Anemia .

Aclarubicin (HCl) produces potentially life-threatening effects which include Congestive heart failure. Careful monitoring is needed with proper medical management.

Aclarubicin (HCl) is known to cause more or less tolerable side effects which are usually transient. These include Alopecia, Anorexia , Nausea, Vomiting .

Warnings / Precautions

Aclarubicin is not recommended for use during pregnancy or lactation. Immunosuppressent drug should not be given, where possible, to patients with acute infection, dosage reduction or withdrawal should be considered if infection develops, until the infection has been controlled. Blood counts and measurement of hemoglobin concentration should be carried out routinely; it helps to predict the onset of bone marrow depression. It must be handled with great care and avoid contact with skin and eyes and should not be inhaled.

Available Brands

None recorded.

Storage Conditions

Aclarubicin (HCl) should be stored IV Inj. IV Inj (reconstituted soln) .

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs